Driverama: Cobra 11 star Erdoğan Atalay and Driverama are officially united in search of the best price for customers selling their used cars
(Munich, Germany): Actor Erdoğan Atalay has a new job: After surviving a corona infection in December 2021, Atalay, who is best known from the RTL series "Alarm für Cobra 11", is bursting with energy. As of now, the series hero is stepping on the gas as the new face of Driverama, the online platform for used cars. At Driverama customers can sell their vehicles quickly and easily. The digital platform uses AI to determine the best possible price in real time.
Erdoğan Atalay recently demonstrated his skill set in the driving seat at a photo shoot to celebrate his new role as Driverama's official brand ambassador. The actor certainly looked the part in Driverama's iconic yellow racing suit as he put his BMW 3-series through its paces. "When I received the request to work with Driverama, I didn't have to think twice, because the brand stands for honesty and fairness. When I was then told I would also be allowed to do a few stunts, it was clear I had made the right decision.“ said Atalay.
„Alarm für Cobra 11 - die Autobahnpolizei" has been broadcast on the RTL channel for more than 25 years and the hugely successful series has now been broadcast in 120 countries. Erdoğan Atalay as inspector Semir Gerkhan stars alongside Pia Stutzenstein, who plays Vicky Reisinger. The action-packed thriller will return to our screens this year, for the first time as a feature-length three-part series. The first installment, titled #jedendrittentag, is scheduled to air in the first quarter of 2022.
Footage from the Driverama photo shoot:
https://www.dropbox.com/sh/kj6c5wjgcxcz5ax/AABaIEushAS5lagxzmwkG0lja?dl=0
Testimonial image film: https://www.youtube.com/watch?v=NTd5MLRTmDk&ab_channel=Driverama
For information on Driverama activities in Germany, visit www.driverama.de.
Contacts
Thomas Reinecke
Tel:+49-172-4540773driverama@dr-p.deAbout news aktuell GmbH
news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Acousia Announces Completion of Patient Enrollment in Phase 2 PROHEAR Study Evaluating ACOU085 (INN: Bimokalner) for the Prevention of Cisplatin-Induced Ototoxicity8.1.2026 09:00:00 CET | Press release
Tübingen, Germany, January 8, 2026 Acousia Therapeutics GmbH, a clinical-stage biotechnology company developing treatments for acute and chronic inner ear hearing loss, announced the completion of patient enrollment in its Phase 2 PROHEAR clinical study. ACOU085 (INN: Bimokalner) is a proprietary, first-in-class small molecule that has demonstrated robust and reproducible efficacy across multiple preclinical hearing loss models, including drug-induced ototoxicity. The PROHEAR Study is a double-blind, randomized, placebo-controlled, split-body, multicenter Phase 2 trial. It enrolled young male patients with metastatic testicular cancer who are scheduled to receive cisplatin-based chemotherapy. While cisplatin is a highly effective chemotherapeutic agent, cumulative doses of ≥300 mg/m² lead to clinically meaningful, permanent hearing loss in the majority of patients. Fifteen leading university hospitals in Germany are participating in this interdisciplinary study. Patients are randomized
Dr. Stefanie Kesting appointed as CEO of Thyssengas7.1.2026 14:06:26 CET | Press release
Dortmund, 06.01.2026 As of January 1, 2026, Dr. Stefanie Kesting has been appointed as the new Chief Executive Officer (CEO) of Thyssengas GmbH. She succeeds Dr. Thomas Gößmann, who will retire at the end of February 2026 after nearly nine years at the helm of the company. The leadership transition was announced in autumn 2025.
30 Years of European Spas: Nature, Natural Remedies and Climate Health as Europe’s Unique Strength7.1.2026 08:59:31 CET | Press release
To mark its 30th anniversary, the European Spas Association (ESPA) has released a special commemorative publication highlighting the strategic role of Europe’s medical spas and climate-health resorts in an era defined by prevention, longevity and sustainable wellbeing.
Forum for a self-reliant and self-determined Europe - the "Sovereign Europe Forum"23.12.2025 08:40:47 CET | Press release
Entrepreneurs, top managers and leaders from United Europe e.V. and European Forum Alpbach (EFA) are founding the Sovereign Europe Forum i.G.
Digital Subsidiary of Austrian State Printing Company Wins Infrastructure Tender for German EU Digital Identity Wallet22.12.2025 15:12:30 CET | Press release
youniqx Identity, a digital subsidiary of the Austrian State Printing Company (OSD), has won a Europe-wide tender, together with partner companies, for the infrastructure of the German EU Digital Identity Wallet (EUDI-Wallet). EU member states are required by EU regulations to provide a national version of an EU-wide valid EUDI-Wallet by the end of 2026. Citizens will be able to use the EUDI-Wallet to prove their personal identity throughout the EU
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
